Clinical Hematology International

Volume 1, Issue 1, March 2019, Pages 2 - 9

Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies

Authors
Mohamed A. Kharfan-Dabaja1, *, Naveen Pemmaraju2, *, Mohamad Mohty3
1Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA
2Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
3Hopital Saint-Antoine, Université Pierre & Marie Curie, INSERM UMRs U938, Paris, France

Peer review under responsibility of IACH

Corresponding Authors
Mohamed A. Kharfan-Dabaja, Naveen Pemmaraju
Received 2 January 2019, Accepted 18 February 2019, Available Online 18 March 2019.
DOI
https://doi.org/10.2991/chi.d.190218.001How to use a DOI?
Keywords
Blastic plasmacytoid dendritic cell neoplasm; Allogeneic hematopoietic cell transplant; Targeted therapies; Overall survival
Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of plasmacytoid dendritic cells. There is no established standard therapy for BPDCN and the efficacy of conventional chemotherapy is limited, with an anticipated median overall survival ranging from 8 to 14 months. No randomized controlled trials have ever been performed to evaluate the benefit of frontline consolidation with an allogeneic hematopoietic cell transplant (allo-HCT) in BPDCN. Yet, offering an allograft has become the de facto option in BPDCN, and remains the only known long-term curative option for these patients, even in the modern era of targeted therapies. In our opinion, allo-HCT is recommended as part of frontline consolidation, especially in patients achieving first complete remission and who are deemed capable of tolerating the procedure, as published data show 3- to 4-year progression-free survival ranging from 69% to 74% in this population. Prompt referral to a transplant center, at the time of a diagnosis of BPDCN, is important to confirm allo-HCT candidacy and to initiate the process of identifying a suitable human leukocyte antigen (HLA)-compatible donor. Because disease relapse remains a major concern, additional strategies, such as post-allograft consolidation/maintenance therapy, are certainly needed to help further improve outcomes. Finally, patients deemed ineligible to receive an allo-HCT, due to lack of response and/or poor performance status, should be considered for enrollment in clinical trials.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Clinical Hematology International
Volume-Issue
1 - 1
Pages
2 - 9
Publication Date
2019/03/18
ISSN (Online)
2590-0048
DOI
https://doi.org/10.2991/chi.d.190218.001How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Mohamed A. Kharfan-Dabaja
AU  - Naveen Pemmaraju
AU  - Mohamad Mohty
PY  - 2019
DA  - 2019/03/18
TI  - Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies
JO  - Clinical Hematology International
SP  - 2
EP  - 9
VL  - 1
IS  - 1
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190218.001
DO  - https://doi.org/10.2991/chi.d.190218.001
ID  - Kharfan-Dabaja2019
ER  -